Creating Value Through Early Phase Trial Design: How the FDA’s Single Phase 3 Pivot Impacts Early Phases

Sponsored by Dr. Vince Clinical Research

In this video interview, Peter Schmidt, PhD, chief scientific officer of Dr. Vince Clinical Research, examines a fundamental change in FDA regulatory strategy: the emergence of the single pivotal Phase III trial as the mainstream pathway for drug approval, a shift he traces to a February New England Journal of Medicine announcement. Schmidt explains that this approach requires sponsors to establish their scientific hypothesis for a drug's mechanism of action much earlier in development, rather than relying on the traditional model of building patient impact evidence later in the process.

Schmidt walks through how this changes the role of each early phase. Phase I, long viewed primarily as a safety study, now needs to also generate an efficacy signal and inform dosing decisions tied to a drug's mechanism. Phase II builds on that foundation by pairing a mechanistic biomarker with a patient-reported or clinical outcome, ideally producing an interim readout that positions a molecule for licensure or partnership before Phase III begins. He also discusses the regulatory and continuity risks that arise when Phase I and Phase II are treated as disconnected projects, including the challenge of establishing a defensible therapeutic dose rather than one based on safety criteria alone.

The conversation offers value for clinical development leaders, regulatory strategists, and emerging biopharma sponsors navigating early-phase trial design. Viewers will come away with a clearer picture of how to build a continuous development pathway, from biomarker selection through dose-response data, that supports a stronger position heading into Phase III and FDA review.